Skip to Content

ARCA biopharma Inc ABIO

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

ARCA biopharma Inc is a clinical development stage biopharmaceutical company. It applies precision medicine approach to develop genetically targeted therapies for cardiovascular diseases. The company's lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, viruses, initially focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation, in patients with chronic heart failure.

Contact
10170 Church Ranch Way, Suite 100
Westminster, CO, 80021
T +1 720 940-2200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type
Employees 14